Windtree Therapeutics : September'23 Corporate Presentation

Windtree Therapeutics

Company Overview

September 2023

(NASDAQ: WINT)

Forward-Looking Statements

This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development activities, or otherwise as to future events. The forward- looking statements provide our current expectations or forecasts of future events and financial performance and may be identified by the use of forward-looking terminology, including such terms as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "will," "should," "could," "targets," "projects," "contemplates," "predicts," "potential" or "continues" or, in each case, their negative, or other variations or comparable terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. These risks and uncertainties are further described in the Company's periodic filings with the Securities and Exchange Commission ("SEC"), including the Company's most recent reports on Form 10-K, and any subsequent quarterly reports on Form 10-Q and current reports on Form 8-K, and any amendments thereto ("Company Filings"). Moreover, we operate in an evolving environment. New risks and uncertainties may emerge from time to time, and it is not possible for management to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Under no circumstances shall this presentation be construed as an offer to sell or as a solicitation of an offer to buy any of the Company's securities. In addition, the information presented in this deck is qualified in its entirety by the Company Filings. The reader should refer to the Company Filings for a fuller discussion of the matters presented here.

2

Multi-Asset / Indication Pipeline with Several Near-Term Milestones

Cardiogenic Shock with Istaroxime as Lead Program

Multi-asset Heart Failure platform for partnership

		Product	Indication	Phase	Development Status / Plans
		Candidates
		Priority Program			•	Lead program
		Istaroxime	Cardiogenic Shock	Phase 2	• Positive Phase 2 study
		• Executing small follow-on studies with planned
					• Studies are intended to transition to Phase 3
					• Positive 2a and 2b data
		Istaroxime	Acute Heart Failure	Phase 2b	•	Augment AHF data with cardiogenic shock data, if
		(completed)		positive and adequate, for phase 3 for AHF with
						partnership
		Oral SERCA2a	Chronic Heart Failure, including	Preclinical	•	Chronic and Acute Heart Failure
		Activators	potentially HFpEF	•	Target for collaboration/partnership
					• Phase 2 data in hypertension and genetically associated
			Treatment Resistant Hypertension			hypertension
		Rostafuroxin	Phase 2b	•	Company holding development to out-license and
		- Genetically Associated
					repositioned for the attractive and large Resistant
						Hypertension market
		KL4 Surfactant	KL4 surfactant Drug/Device Tx for		• Global out-license to Lee's Pharma
		RDS and potential other	Phase 2b
		and AEROSURF	• Lee's Pharma responsible for all costs of development
		applications

4

Istaroxime

Cardiogenic Shock

Potential to transform the standard of care for critical patients

5